Company intelligence / Profile preview

C-Reveal Therapeutics

Boston, Massachusetts, United States

Ownership: Private
Employees: ~1
Development stage: Other

Overview

Preclinical programs have identified and validated proprietary cancer-specific enzyme targets and generated small-molecule drug leads with in vitro proof-of-concept that inhibiting these enzymes can expose tumors to immune attack and potentially improve response rates to existing immunotherapies; no human clinical data reported yet.[2]

Therapeutic areas: Oncology
Modalities: Small moleculeAntibodyBiologic
Industry: Biotech

Partnerships

Evotec (drug discovery partner for high-throughput screening and early R&D)[2]

Beyond the preview

Go deeper on C-Reveal Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on C-Reveal Therapeutics.

Explore the full profile